Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.small Co.2 Regulatory News (BSC)

Share Price Information for Br.small Co.2 (BSC)

Share Price is delayed by 15 minutes
Get Live Data
50.55    0.00 (0.00%)
Bid:
49.60
Ask:
51.50
Spread: 1.90 (3.831%)
Market Cap: £193.32m
BSC Live PriceLast checked at - London Stock Exchange

Intraday Br.small Co.2 Share Chart

Interim Management Statement

11 May 2012 07:00

RNS Number : 1242D
British Smaller Companies VCT2 Plc
11 May 2012
 



 

British Smaller Companies VCT2 plc ("the Company")

 

Interim Management Statement

 

British Smaller Companies VCT2 plc presents its interim management statement for the period from 1 January 2012 to the date of this announcement. This constitutes the Company's first interim management statement for the financial year ending 31 December 2012, as required by Rule 4.3 of the Disclosure and Transparency Rules. A copy of this interim management statement can be found at www.yfmep.com.

 

The total return at 31 March 2012, calculated by reference to the net asset value per Ordinary share and the cumulative dividends paid and proposed, is 99.2 pence per Ordinary share. This represents an increase of 0.7 pence per Ordinary share in the quarter, which is substantially a result from an overall increase in the value of the investment portfolio.

 

The unaudited net asset value per Ordinary share as at 31 March 2012 was 69.2p (31 December 2011: 68.5p).

 

The number of Ordinary shares in issue at 31 March 2012 was 33,233,622 (31 December 2011: 23,330,802). In addition at 31 March 2012 the Company held 929,122 Ordinary shares in Treasury (31 December 2011: 929,122).

 

During the quarter the Company, in connection with the offer for subscription launched in October 2011 ("Offer"), allotted 9,902,820 new Ordinary shares at a price of 70.5 pence per share, for gross proceeds of £6.98 million;

 

Following the quarter end the Company opted to extend the Offer beyond its original £10m limit in order to allot a further 5,080,416 new Ordinary shares. In total the Company raised gross proceeds of £10.6 million under the Offer.

Net assets at 31 March 2012 comprised the following:

£000

% of net assets

Unquoted investments at fair value

9,428

41.0

Quoted investments at bid price

2,085

9.1

Gilt investments

917

4.0

Total investments

12,430

54.1

Cash and cash equivalents

10,406

45.2

Other net current assets

161

0.7

Net assets

22,997

100.0

 

The ten largest investments by valuation at 31 March 2012 were as follows:

 

£000

% of net assets

Digital Healthcare Limited

1,278

5.6

Primal Pictures Limited

1,272

5.5

Deep-Secure Ltd

1,149

5.0

Sirigen Group Limited

917

4.0

Displayplan Holdings Limited

700

3.0

Immunobiology Limited

615

2.7

Bluebell Telecom Group Limited

608

2.6

PowerOasis Limited

500

2.2

Bagel Nash Limited

407

1.8

Harvey Jones Holdings Limited

392

1.7

Top ten investments

7,838

34.1

Other investments

3,675

16.0

Gilt investments

917

4.0

Total investments

12,430

54.1

 

 

During the three months ended 31 March 2012 the Company invested a total of £1.2 million.

In January 2012 £0.7 million was invested as part of the management buyout of the retail display group Displayplan Holdings Limited. In February 2012 a further £0.06 million was invested into portfolio business Sirigen Group Limited as part of a £1 million internal growth capital round, supporting the further commercialisation of its innovative technology. In March 2012 £0.3 million was invested as part of the £2 million buyout of Selima Limited, a supplier of payroll and expenses software predominately to public sector customers. In addition £0.15 million was invested into shares in existing portfolio company EKF Diagnostics Plc, an AIM-listed international diagnostics group.

 

During the quarter further deferred cash proceeds of £64,000 have been recognised in respect of the Company's investment in DxS Limited. This takes total proceeds to £2.65 million representing a 16.3x cash return on the original investment. Also during the quarter the Company received £164,000 of proceeds following the sale of its holding in Patsystems plc via a trade sale to ION Group plc in January 2012, representing a small uplift on the December 2011 valuation; £17,000 of proceeds from the partial sale of shares in AiM quoted Tikit Group plc and £140,000 on the early redemption of the remaining loan from RMS Group Holdings Limited.

 

Performance

Your Company's portfolio valuation has stood up well this quarter, showing an increase overall of 0.7p per Ordinary share as several investee businesses recorded positive results. The total return, calculated by reference to the net asset value plus cumulative dividends paid and proposed has increased by 0.7 pence to 99.2 pence per Ordinary share, with the cumulative dividend now representing 30.0 pence per Ordinary share.

 

Dividend Re-investment scheme

The Company continues to operate a dividend re-investment scheme which allows Shareholders the opportunity to build further capital value by electing to receive ordinary shares in the Company, credited as fully paid, instead of receiving dividends in cash.

 

Investor Workshops

The Company remains committed to enhancing Shareholder communications and has presented annual investor workshops for a number of years which have proved very popular with Shareholders. The most recent event held on 9 February 2012 at the Royal College of Surgeons welcomed over 150 Shareholders.

 

Outlook

In spite of the ongoing economic uncertainty in the markets significant progress continues to be made across the portfolio. There is also evidence of increasing new investment opportunities as businesses take advantage of changing market conditions and vendors look for equity solutions. The proposed changes to the rules defining eligible VCT investments are also expected to lead to an increased level of investment opportunities. Your Board expects an increased level of attractive investment opportunities over the short and medium term. Following the successful fundraising offer that closed on 5 April 2012 the Company is in a strong position to take full advantage of this market opportunity.

 

11 May 2012

 

For further information please contact:

 

David Hall YFM Private Equity Limited Tel: 0113 294 5055

Claes Spang Singer Capital Markets Limited Tel: 0203 205 7500

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSMMGMKVGVGZZM
Date   Source Headline
23rd Sep 201910:10 amRNSPayment of Dividend and Issue of Equity
14th Aug 20199:14 amRNSHalf-year Report
10th May 20199:43 amRNSPayment of Final Dividend and Issue of Equity
7th May 20192:18 pmRNSResult of AGM and Change of Chairman
7th May 20199:53 amRNSInterim Management Statement
4th Apr 201912:13 pmRNSDirector/PDMR Shareholding
4th Apr 201912:13 pmRNSDirector/PDMR Shareholding
4th Apr 201912:11 pmRNSDirector/PDMR Shareholding
4th Apr 201912:10 pmRNSDirector/PDMR Shareholding
1st Apr 20193:51 pmRNSIssue of Equity
1st Apr 20193:44 pmRNSIssue of Equity and Close of Offers
27th Mar 201910:19 amRNSTransaction in Own Shares and Net Asset Value
26th Mar 20194:29 pmRNSPublication of Supplementary Prospectus
26th Mar 20194:27 pmRNSPublication of Supplementary Prospectus
22nd Mar 201911:48 amRNSAnnual Financial Report
6th Mar 201911:09 amRNSAppointment of non-executive director
15th Feb 20199:56 amRNSPayment of interim dividend and issue of shares
11th Feb 201911:15 amRNSClose of Offers to New Applications
11th Feb 201911:15 amRNSClose of Offers to New Applications
28th Jan 20193:00 pmRNSUtilisation of over-allotment facility
28th Jan 20193:00 pmRNSUtilisation of over-allotment facility
7th Jan 20192:15 pmRNSDividend Declaration
7th Jan 20191:15 pmRNSStatement re Prospectus
7th Jan 20191:15 pmRNSStatement re Prospectus
21st Dec 20189:13 amRNSDisposal
20th Dec 201810:20 amRNSTransaction in Own Shares
27th Nov 20186:07 pmRNSPublication of Prospectus
27th Nov 20185:49 pmRNSPublication of Prospectus
21st Nov 20181:00 pmRNSUnaudited Interim Results to 30 September 2018
23rd Oct 20181:00 pmRNSStatement re proposed joint fundraising
23rd Oct 20181:00 pmRNSStatement re proposed joint fundraising
28th Sep 20189:54 amRNSPayment of dividend and allotment of shares
27th Sep 20181:27 pmRNSTransaction in Own Shares
17th Aug 20188:07 amRNSHalf-year Report
25th Jun 201811:52 amRNSTransaction in Own Shares
11th May 201810:01 amRNSPayment of final dividend and allotment of shares
9th May 20182:36 pmRNSResult of Annual General meeting
9th May 20189:54 amRNSInterim Management Statement
28th Mar 20188:27 amRNSTransaction in Own Shares
16th Mar 20181:43 pmRNSAnnual Financial Report
16th Feb 20189:50 amRNSIssue of Equity
12th Feb 201810:50 amRNSDirector Declaration
26th Jan 20189:24 amRNSClose of Offer to New Subscriptions
11th Jan 20188:06 amRNSOffer for Subscription
20th Dec 20178:50 amRNSPurchase of own securities and total voting rights
20th Dec 20178:50 amRNSLaunch of Top-up Offer
30th Nov 20171:28 pmRNSInterim Management Statement to 30 September 2017
20th Oct 20172:12 pmRNSTransaction in Own Shares
29th Sep 20179:47 amRNSPayment of interim dividend and issue of shares
29th Sep 20179:36 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.